QualityDipStocks / Health Care · Life Sciences Tools
Agilent Technologies A
Not in a dip by our rules: 4% below its 52-week high.
A quality company trading well above our fair value estimate, 6% over its Market Value.
- Fair value est.
- $70.94−59%
- Market Value
- $164.62price +6%
- Off 52-wk high
- −4%
- Risk vs market
- Below marketbeta 0.89
5 bullish · 5 bearish See why
Key levels
Every level vs today’s $174.87
- Fair value est.base case$70.94−59.4%
- 52-wk lowlowest close, 1 year$110.24−37.0%
- Market Valueavg paid since Aug 26$164.62−5.9%
- PriceFri Oct 30 close$174.87you are here
- 52-wk highhighest close, 1 year$181.48+3.8%
Fair value estimate
How the range is computed
Ten-year free-cash-flow DCF. Same 10-year free-cash-flow model as the base: discount rate 9.5% ±1 point and growth 3.0% ±2 points. Bear = 10.5% and 1.0%; bull = 8.5% and 5.0% (both fade to 3%). A model estimate from public filings, not a forecast of where the price will go.
Price is above even the bull case.
What the price implies To be worth today’s price, A’s free cash flow would need to grow about 19% a year for five years; our estimate uses 3%.
Risk vs market
How risk vs market is measured
One year of daily returns (Oct 30 to Oct 30, 252 sessions). Beta = how much A moved for each 1% move in the S&P 500 (SPY); 1.0 moves with the market. Volatility is the yearly standard deviation of daily returns. Past behavior, not a forecast.
Moves a bit less than the market, and its own price swings are 2.5× the S&P 500’s.
- Beta vs S&P 500
- 0.89
- Volatility
- 33% vs 13% SPY
- Correlation SPY
- 0.35
- Correlation QQQ
- 0.28
Bull vs bear
Rule-based from the data on this page, strongest first. Not advice.
Top bullish points 5 of 5
ProfitabilityReturn on equity of 21% over the last 12 months.
GrowthSales grew 9% to $7.4B over the last 12 months vs the 12 months before (SEC filings).
Cash returnsFree cash flow grew 16% over the last 12 months vs the 12 months before.
ProfitabilityOperating margin of 22%, above the 13% median for the 89 Health Care companies we cover.
QualityPasses all four of our quality checks: cash generation, returns on capital, growth and balance sheet.
Top bearish points 5 of 5
ValuationOur DCF fair value estimate is $70.94, 59% below the price.
ValuationP/E of 34.4× is 20% above its own average of 28.7× at the last 3 fiscal year-ends.
GrowthSales grew 0.5% a year over the last three fiscal years, below the 7.3% median for the 101 Health Care companies we cover.
ValuationEV/EBITDA of 27.1×, above the 17.0× median for the 55 Health Care companies we cover.
ValuationTrades 6.2% above its Market Value of $164.62, the average price paid since the Aug 26 filing.
Who’s talking about it
Notable investors, executives, analysts and public figures on Agilent Technologies in the last 48 hours. Headlines as published, each linked. Their words, not ours.
No notable mentions in the last 48 hours. Checked Nov 1, 9:09 PM ET.
Compare with peers
Closest in size in Life Sciences Tools
All fundamentals
P/E 34.4 · FCF yield 2.6% · ROE 21%
Valuation
- P/E
- 34.4×3-yr-end avg 28.7× · Health Care median 29.2×
- Price / FCF
- 39.1×
- FCF yield
- 2.6%
- EV / EBITDA
- 27.1×
- Price / sales
- 6.71×
- Price / book
- 6.72×
- Market cap
- $49.5Bprice × diluted shares
- Enterprise value
- $51.7B
Growth
- Revenue, 12 months
- $7.4B
- Sales growth, 12 months
- +8.6%vs the 12 months before
- Sales growth, 3 yrs
- +0.5%/yrfrom FY2022
- Diluted EPS, 12 months
- $5.07
- EPS growth, last FY
- +3.2%
- Net income, 12 months
- $1.4B
- Net income growth
- +18%12 months vs before
Profitability
- Gross margin
- 53.8%
- Operating margin
- 22.2%
- Net margin
- 19.5%
- FCF margin
- 17.2%
- Return on equity
- 21%
- Return on invested capital
- 15%
Balance sheet
- Cash & short-term inv.
- $1.8B
- Total debt
- $3.9B
- Net cash
- −$2.2B
- Debt / equity
- 0.54×
- Interest coverage
- 15.5×operating income / interest
Cash flow & returns
- Free cash flow, 12 months
- $1.3B
- FCF growth, 12 months
- +16%
- Dividend yield
- 0.58%$286M paid
- Payout ratio
- 20%
- Buybacks, 12 months
- $380M0.8% of market cap
- Share count, 1 year
- −0.7%diluted shares vs a year ago
- Stock-based comp
- $131M
Trailing 12 months to Jul 31, 2026; balance sheet at Jul 31, 2026. From Agilent Technologies’s SEC filings. Sparklines show up to six fiscal years. n/a means we don’t hold that number, with the reason. How each is computed.
Valuation details
DCF $70.94 · MV $164.62 · FCF value $108.65
Assumes 3.0% growth for 5 years (revenue grew 0.5% a year FY22–FY25; floored at 3%), fading to 3%; 9.5% discount rate, 3% terminal growth. FCF base $4.48 a share (trailing 12 months to Jul 31, 2026), from the 10-Q filed Sep 1, 2026. Net debt $2.2B, not deducted.
Setup & signals
No setup armed
No setup armed, so there’s no trigger or stop to track yet. Reversal signal rules only arm once a company is in a dip.
Momentum & 52-week range
RSI 55 · 5 days +1.0%
The business
FCF $1.3B · Sales +8%
- Free cash flow, 12 months$1.3B
- Free-cash-flow yield2.5%
- Free-cash-flow margin17%
- Gross margin54%
- Operating margin22%
- Return on invested capital11%
- Return on equity21%
- Sales growth (latest quarter vs year-ago quarter)+8%
- Net debt / EBITDA1.1×
Next report
Nov 23
- DateMon Nov 23
- Consensus EPS$1.72
- Year-ago EPS$1.59
- QuarterOct/2026
From Nasdaq’s earnings calendar. A report resets Market Value.
Information only, not investment advice. Fair value estimates and talking points are rule-based model output from public data and can be wrong; stop levels are reference points, not orders. How every number is computed.
Get a text when A fires a reversal signal
One text when a published rule fires on A or any of the 333 quality companies we track: the ticker, the price, the stop and a link to the numbers. Nothing else.